Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486713 · ClinicalTrials.gov registry record · Phase 4
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
A Phase 4 study of Glioma and Cholangiocarcinoma, sponsored by Rigel Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT07486713 is a Phase 4 study of Glioma and Cholangiocarcinoma that is actively recruiting participants, run by Rigel Pharmaceuticals. The registered enrollment target is 16 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07486713, a Phase 4 study of Glioma and Cholangiocarcinoma, is actively recruiting participants, sponsored by Rigel Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Conditions Studied
Interventions
- DRUG Olutasidenib
- DRUG CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
Study Locations (2)
California
- UCI Irvine Health - Orange
New York
- New York Presbyterian Hospital-Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07486713
The ClinicalTrials.gov registry entry for NCT07486713 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (92% lower). The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which Olutasidenib is the first listed.
NCT07486713 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT07486713 about?
NCT07486713 is a clinical study titled "Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies". A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
What is the current status of trial NCT07486713?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2026-02-23. Estimated completion is 2027-06-30.
What conditions does trial NCT07486713 study?
This clinical trial studies the following conditions: Glioma, Cholangiocarcinoma, Solid Tumor Malignancies, AML (Acute Myeloid Leukemia).
What interventions are being tested in trial NCT07486713?
The interventions under investigation include: Olutasidenib (DRUG), CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates (DRUG).
Who is sponsoring clinical trial NCT07486713?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07486713 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
-
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.